+1-206-701-6702
+44-020-8133-4027
+81-50-5539-1737
+91-848-285-0837
Lentiviral vectors are used as a means to deliver foreign genetic material into another cell. These vectors are developed from lentivirus, a type of retrovirus, which are characterized by their long incubation period and can infect both dividing and non-dividing cells. The lentiviral vectors are derived from human immunodeficiency virus (HIV) and hence, these vectors are highly efficient vehicles for in vivo gene delivery for gene therapies.
Market players are focusing on robust production of high quality lentiviral vectors through various inorganic growth strategies such as collaborations and agreements, which is expected to boost the global lentiviral vectors market growth over the forecast period. For instance, in June 2019, Servier Laboratories, an international pharmaceutical company, collaborated with Yposkesi, Inc, a contract development and manufacturing organization (CDMO), for the production of high quality lentiviral vectors.
The global lentiviral vectors market is estimated to be valued at US$ 176.9 million in 2020 and is expected to exhibit a CAGR of 18.3% over the forecast period (2020-2027).
Figure 1. Global Lentiviral Vectors Market Share (%) in Terms of Value, By Region, 2019
Increasing research and development activities by market players is expected to propel the market growth over the forecast period
Various manufacturers are engaged in research and development activities for novel lentiviral gene therapies, which is expected to drive growth of the global lentiviral vectors market. For instance, on May 14, 2020, AVROBIO, Inc., a clinical-stage gene therapy company, presented pre-clinical data AVR-RD-03 for Pompe disease. The study showcased the potential of lentiviral gene therapy approach for Pompe disease manifestations in the muscle and central nervous system (CNS).
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2019: | US$ 176.9 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 18.3% | 2027 Value Projection: | US$ 573.6 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific Sirion-Biotech GmbH, Vigene Biosciences, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, and bluebird bio, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Increasing agreements and collaborations by market players is expected to drive the market growth over the forecast period
Key players are focusing on various inorganic growth strategies such as agreements and collaborations, which is expected to growth of the lentiviral vectors market over the forecast period. For instance, in May 2017, bluebird bio, Inc. entered into a license agreement with Novartis Pharma AG. Under this agreement, Novartis will non-exclusively license certain bluebird patent rights related to lentiviral vector technology to develop and commercialize therapies for oncology.
Figure 2. Global Lentiviral Vectors Market Value (US$ Mn), 2016 – 2027
Global Lentiviral Vectors Market – Impact of Coronavirus (Covid-19) Pandemic
The U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020.
The guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, compliance with good clinical practice (GCP), and minimize the risks of trial integrity during the COVID-19 public health emergency.
The appendix of the guidelines has also provided answers to some general questions, which the U.S. Food and Drug Administration (FDA) had received from various sponsors and researchers about conducting clinical trials during the COVID-19 public health emergency.
Lentiviral Vectors Market Restraint
The major factors restraining growth of the lentiviral vectors market is potential generation of replication competent virus and the possibility of oncogenesis through insertional mutagenesis.
Key Players
Major players operating in the global lentiviral vectors market include Thermo Fisher Scientific Sirion-Biotech GmbH, Vigene Biosciences, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, and bluebird bio, Inc.
Lentiviral vectors are potential gene transfer vehicles used in both research and gene therapy applications. Lentiviral vectors have the capacity to stably express a gene of interest in non-dividing and diving cells, which makes them efficient vehicles for gene transfer. Lentiviral vectors are used for the treatment of various rare genetic disorders such as β-thalassemia, X-linked Adrenoleukodystrophy, X-linked severe combined immunodeficiency (SCID-X1) and Metachromatic Leukodystrophy. Moreover, various market players are focusing on increasing their research and development activities for gene therapies including lentiviral vectors, in order to enhance their product portfolio, which is expected to drive growth of the global lentiviral vectors market over the forecast period. For instance, in May, 2019, Avrobio Inc. initiated a phase I/II trial for lentiviral vector gene therapy including AVR-RD-02 for patients with type 1 Gaucher disease.
Market Dynamics
Market players are focusing on adopting various inorganic growth strategies such as agreements, acquisitions, partnerships, and collaborations, in order to strengthen their market presence, which is expected to drive growth of the global lentiviral vectors market over the forecast period. For instance, on April 07, 2020, SIRION Biotech GmbH announced that it entered into an agreement with Beam Therapeutics, a biotechnology company, which is focusing on the use of CRISPR technology for the development of advanced genetic medicines. Under this agreement, SIRION Biotech GmbH provided the non-exclusive access of its proprietary lentiviral transduction enhancer LentiBOOST, to Beam Therapeutics for clinical development and commercialization of CAR-T programs.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
